Navigation Links
GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
Date:12/8/2008

LONDON, and PHILADELPHIA, Dec. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 in cash per share without interest and less any required withholding taxes, until 12:00 midnight EST on Friday, December 12, 2008, unless the tender offer is further extended. The tender offer was originally scheduled to expire at 12:00 midnight EST on Wednesday, December 10, 2008.

GSK has extended the tender offer in connection with the addition of SmithKline Beecham Corporation, a wholly-owned subsidiary of GSK, as a bidder, as defined in the Securities Exchange Act of 1934, as amended, with respect to the tender offer.

As of 5 p.m., EST, on December 5, 2008, approximately 3,466,063 shares of Genelabs common stock have been tendered and not withdrawn pursuant to the tender offer, representing approximately 7.8% of the outstanding shares of Genelabs common stock on a fully diluted basis.

The tender offer was commenced on November 12, 2008 pursuant to a previously announced Agreement and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone Acquisition Corporation and SmithKline Beecham Corporation.

All other terms and conditions of the tender offer remain the same, including the condition that, at the expiration of the offer, there have been validly tendered and not withdrawn that number of shares which, together with the number of shares, if any, then beneficially owned by GSK and its wholly-owned subsidiaries, constitutes at least 90 percent of the total number of the then outstanding Genelabs shares on a fully di
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
2. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
3. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
4. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
5. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
6. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
7. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
8. GlaxoSmithKline To Post Quarterly US Grants Report
9. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
10. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
11. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Baltimore (UMB) BioPark today announced that Gliknik Inc., ... the BioInnovation,Center, located in UMB BioPark,s Building Two., ... autoimmune diseases,and cancer, the foundation of which resulted ... and Chairman of the Department of,Otorhinolarynogology, University of ...
... PALM BEACH, Fla., Jan. 9 Workforce Alliance, ... in Palm Beach,County, is closing a grant program ... and prepare for employment in the life sciences ... The Workforce Alliance,s expiring Biotechnology Training Grant was,funded ...
... 9 PAREXEL International,Corporation (Nasdaq: PRXL ), ... Eduard E. Holdener, M.D., formerly Head,of Global Pharmaceutical ... to its Board of Directors., Dr. Holdener ... of NovImmune. The biotechnology Company develops new therapeutic,agents ...
Cached Biology Technology:University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two 2Workforce Alliance Concludes Three-Year Biotech Training Program 2PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors 2PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors 3PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors 4
(Date:5/24/2013)... years, microRNAs (miRNAs) and other non-coding RNAs are ... specific proteins. In recent years they have emerged ... to establish tissue origin for cancers of unknown ... screen for disease, but clinically tractable, diagnostic methods ... not currently available. In this issue of the ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery ... grasses , Within the genome of each species, ... little change in position and sequence over millions of ... of these evolutionarily stable sequences, so-called conserved noncoding sequences ... genes or the condensation of chromosomes, but the function ...
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... This release is available in German . ... and sperm cells in humans, chromosomes are broken and rearranged ... research group of Franz Klein, professor for genetics at the ... analyzed this process at high resolution. The surprising observations regarding ...
... , 221.10.254.64 NOAA scientists have developed a population ... to the size of the haddock population. The model ... cause alternate stable population levels in Georges Bank herring. ... management implications. In a study to be published ...
... Mich. --- Lakes, streams and wetlands are not isolated ... colleagues are pioneering a new field of research to ... Patricia Soranno, associate professor of fisheries and wildlife, ... to gauge land use and climate change,s impact on ...
Cached Biology News:The machinery for recombination is part of the chromosome structure 2The machinery for recombination is part of the chromosome structure 3Atlantic herring population trends linked to egg predation by haddock 2Atlantic herring population trends linked to egg predation by haddock 3MSU professor launches new field of water research, nets $2.2 million NSF grant 2
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Biology Products: